fig4

Fra-1 affects chemotherapy sensitivity by inhibiting ferroptosis in gastric cancer cells

Figure 4. Fra-1 binds to the G6PD promoter and transcriptionally regulates its expression. (A-D) Effects of overexpression/silencing of Fra-1 on G6PD mRNA levels in GC cells AGS and HGC27 detected by RT-qPCR assay; (E) Schematic diagram of G6PD promoter binding motif with Fra-1 DNA; (F) Prediction of possible binding sites of Fra-1 with the G6PD promoter using the JASPAR database; (G and H) Validation of the binding site of Fra-1 to G6PD using ChIP-qPCR experiments; (I and J) Detection of the binding of Fra-1 to the 6th binding site of G6PD using wild-type and mutant dual luciferase reporter gene vectors for the 6th binding site of G6PD in GC cells AGS and HGC27. All experiments were performed with three technical replicates. ns, no significant difference. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Fra-1: Fos-related antigen-1; G6PD: glucose-6-phosphate dehydrogenase; GC: gastric cancer.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/